Inventiva (NASDAQ:IVA) Stock Price Down 7% – Time to Sell?

by · The Markets Daily

Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report) shares were down 7% on Wednesday . The company traded as low as $4.36 and last traded at $4.3440. 1,059,394 shares were traded during trading, an increase of 57% from the average session volume of 676,366 shares. The stock had previously closed at $4.67.

Analysts Set New Price Targets

A number of brokerages have commented on IVA. Cantor Fitzgerald started coverage on shares of Inventiva in a research report on Friday, July 17th. They set an “overweight” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Inventiva presently has a consensus rating of “Buy” and a consensus target price of $15.38.

Read Our Latest Report on Inventiva

Inventiva Stock Performance

The firm has a 50 day moving average of $4.55 and a 200-day moving average of $5.00.

Hedge Funds Weigh In On Inventiva

Hedge funds have recently added to or reduced their stakes in the company. Creative Planning purchased a new position in Inventiva in the 2nd quarter worth about $32,000. Virtu Financial LLC purchased a new stake in Inventiva during the fourth quarter worth $60,000. XTX Topco Ltd bought a new stake in Inventiva during the 4th quarter valued at $84,000. Cerity Partners LLC bought a new stake in Inventiva during the 4th quarter valued at $93,000. Finally, NewEdge Advisors LLC purchased a new position in shares of Inventiva in the 3rd quarter valued at $116,000. 19.06% of the stock is currently owned by institutional investors.

About Inventiva

(Get Free Report)

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.

Featured Articles